98 related articles for article (PubMed ID: 23259783)
1. Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients.
Halamkova J; Kiss I; Pavlovsky Z; Tomasek J; Jarkovsky J; Cech Z; Bednarova D; Tucek S; Hanakova L; Moulis M; Zavrelova J; Man M; Benda P; Robek O; Kala Z; Penka M
Neoplasma; 2013; 60(2):151-9. PubMed ID: 23259783
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer.
Smolarz B; Blasiak J; Kulig A; Romanowicz-Makowska H; Dziki A; Ulanska J; Pander B; Szewczyk T
J Exp Clin Cancer Res; 2001 Jun; 20(2):247-52. PubMed ID: 11484982
[TBL] [Abstract][Full Text] [Related]
3. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
[TBL] [Abstract][Full Text] [Related]
5. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes.
Margaglione M; Grandone E; Vecchione G; Cappucci G; Giuliani N; Colaizzo D; Celentano E; Panico S; Di Minno G
Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2082-7. PubMed ID: 9351375
[TBL] [Abstract][Full Text] [Related]
7. 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.
Burzotta F; Iacoviello L; Di Castelnuovo A; Zamparelli R; D'Orazio A; Amore C; Schiavello R; Donati MB; Maseri A; Possati G; Andreotti F
J Thromb Thrombolysis; 2003 Dec; 16(3):149-54. PubMed ID: 15087600
[TBL] [Abstract][Full Text] [Related]
8. Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy.
Xu F; Liu H; Sun Y
Ren Fail; 2016; 38(1):157-62. PubMed ID: 26616527
[TBL] [Abstract][Full Text] [Related]
9. The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis.
Lorente L; Martín MM; Borreguero-León JM; Barrios Y; Solé-Violán J; Ferreres J; Labarta L; Díaz C; Jiménez A
PLoS One; 2015; 10(6):e0129565. PubMed ID: 26066833
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
[TBL] [Abstract][Full Text] [Related]
11. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
Błasiak J; Smolarz B
Acta Biochim Pol; 2000; 47(1):191-9. PubMed ID: 10961693
[TBL] [Abstract][Full Text] [Related]
13. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study.
van Goor ML; Gómez García E; Leebeek F; Brouwers GJ; Koudstaal P; Dippel D
Thromb Haemost; 2005 Jan; 93(1):92-6. PubMed ID: 15630497
[TBL] [Abstract][Full Text] [Related]
14. 4G/5G Polymorphism of the plasminogen activator inhibitor-1 gene is associated with multiple organ dysfunction in critically ill patients.
Huq MA; Takeyama N; Harada M; Miki Y; Takeuchi A; Inoue S; Nakagawa T; Kanou H; Hirakawa A; Noguchi H
Acta Haematol; 2012; 127(2):72-80. PubMed ID: 22134139
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.
Loktionov A; Watson MA; Stebbings WS; Speakman CT; Bingham SA
Cancer Lett; 2003 Jan; 189(2):189-96. PubMed ID: 12490312
[TBL] [Abstract][Full Text] [Related]
16. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group.
Hermans PW; Hibberd ML; Booy R; Daramola O; Hazelzet JA; de Groot R; Levin M
Lancet; 1999 Aug; 354(9178):556-60. PubMed ID: 10470700
[TBL] [Abstract][Full Text] [Related]
17. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
[TBL] [Abstract][Full Text] [Related]
18. PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
Meigs JB; Dupuis J; Liu C; O'Donnell CJ; Fox CS; Kathiresan S; Gabriel SB; Larson MG; Yang Q; Herbert AG; Wilson PW; Feng D; Tofler GH; Cupples LA
Obesity (Silver Spring); 2006 May; 14(5):753-8. PubMed ID: 16855181
[TBL] [Abstract][Full Text] [Related]
19. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes.
Iwai N; Shimoike H; Nakamura Y; Tamaki S; Kinoshita M
Atherosclerosis; 1998 Jan; 136(1):109-14. PubMed ID: 9544737
[TBL] [Abstract][Full Text] [Related]
20. The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.
Yıldırım ME; Karakuş S; Kurtulgan HK; Kılıçgün H; Erşan S; Bakır S
Biochem Genet; 2017 Aug; 55(4):314-321. PubMed ID: 28303356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
